RxDoctor Payments Data

Ali Sadoughi, MD

Pulmonary Disease · Saint Louis, MONPI 1699933879

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Olympus America Inc. at 36.7% of the total. Reporting peaked in 2024 at $36,911 and has fallen 55.7% since, to $16,336 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,393in general payments, 2019–2025

Across 148 payments — averaging $590.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$32K
  • Merit Medical Systems Inc$23K
  • Intuitive Surgical$9K
  • Olympus Medical Systems Corporation$7K
  • Veran Medical Technologies, Inc.$6K
  • Siemens Medical Solutions USA, Inc.$2K
  • plus $8K from 17 others
$3,750in research payments, 2019–2025

Across 1 payment — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gyrus ACMI, Inc.$4K

What the payments were for

  • Consulting fees$40,22646%
  • Speaking & faculty fees$26,05830%
  • Travel & lodging$9,73611%
  • Food & beverage$3,4484%
  • Education$7,6259%
  • Gifts$3010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,393 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$83,734
Medicare patients
133
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$35,176
Breo ElliptaFluticasone/Vilanterol69$26,958
Albuterol Sulfate HfaAlbuterol Sulfate475$15,151
Atrovent HfaIpratropium Bromide22$12,092
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$10,737
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$7,910
Incruse ElliptaUmeclidinium Bromide14$4,674
SymbicortBudesonide/Formoterol Fumarate16$2,982
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,736
Fluticasone Propionate18$251
Montelukast Sodium14$72
Prednisone11$31

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →